Portfolio Companies

Clinical company developing platform of neuromodulators for neurology indications.

Visit Site

Preclinical company developing immunotherapy platform for oncology applications.

Visit Site

Preclinical company bringing directed chemical evolution to small molecule drug discovery.

Visit Site

Clinical stage company targeting Natural Killer cells for immuno-oncology applications.

Visit Site

Preclinical company developing novel treatments for rare disease.

Visit Site

Clinical stage company using AI genomics for early cancer detection.

Visit Site

ImCheck Therapeutics today announced the publication of preclinical data elucidating the fundamental role of butyrophilins (BTNs) in the activation of V gamma 9 V delta 2 (γ9δ2) T cells leading to an anti-tumor immune response in the peer-reviewed journal, Cell Reports. The publication, titled “BTN2A1, An Immune-checkpoint Targeting Vγ9Vδ2 T Cell Cytotoxicity Against Malignant Cells” summarizes the findings of the interaction between specific BTN subtypes that efficiently activate Vγ9Vδ2 T cells, an important subset of cytotoxic γδ T cells. In addition, the publication demonstrates that an anti-BTN2A1-specific antibody is able to inhibit the cytotoxic function of the Vγ9Vδ2 T cells. The article was authored by ImCheck scientists in collaboration with the laboratory of Prof. Daniel Olive, Professor of Immunology and Director of the Oncology Research Programs at Aix Marseille University and the company’s scientific founder.https://www.imchecktherapeutics.com/all-press-release/news/imcheck-publishes-seminal-paper-in-cell-reports-elucidating-how-butyrophilins-activate-vg9vd2-t-cell-function-against-tumor-cells/

Visit Site

Clinical stage company developing novel immuno-oncology antibodies targeting gamma delta T-cells.

Visit Site

Preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.

Visit Site

Preclinical stage company discovering breakthrough gene editing systems for curing disease.

Visit Site

Clinical company developing therapeutics for rare brain tumors.

Visit Site

Commercial company developing gene therapies for rare immunology disorders.

Visit Site

Clinical stage company developing therapeutics for rare dermatological disorders.

Visit Site

Clinical stage company developing therapeutics targeting key biological pathways in fibrosis.

Visit Site

Clinical stage company developing gene-editing platform for oncology and rare diseases.

Visit Site

Preclinical company developing antibody-based immunotherapies.

Visit Site

Preclinical company developing platform to correct RNA expression in neurology, oncology and rare diseases.

Visit Site